RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease

An Open-Label Dose-Escalation Phase I Study to Asses the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RG2133 (2',3',5'-Tri-O-Acetyluridine) in the Treatment of Inherited Mitochondrial Diseases

Status

Terminated

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00060515

Enrollment

Registered

2003-05-08

Start date

Unknown

Completion date

Unknown

Last updated

2005-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mitochondrial Diseases

Brief summary

The objective of the study is to determine the safety and tolerability of RG2133 in patients with Mitochondrial Disease.

Interventions

DRUGRG2133 (2',3',5'-tri-O-acetyluridine)

Study design

Allocation

NON_RANDOMIZED

Primary purpose

TREATMENT

Eligibility

Sex/Gender

ALL

Age

3 Years to No maximum

Healthy volunteers

Inclusion criteria

Mitochondrial Disease

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026